Navigation Links
Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
Date:12/1/2011

ar time. Nor can there be any guarantee that any such products will achieve any particular levels of revenue in the future. In particular, management's expectations could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; unexpected manufacturing issues; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2010, the Group's
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
2. Genentech and Novartis Remain Image Leaders in Oncology and Hematology
3. FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD
4. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
5. With the Recent Launch of Novartiss Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch
6. VIDEO from Novartis Available on thenewsmarket.com: Novartis Presents Data about Tasigna in Treatment of Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia
7. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
8. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
9. Novartis Class Awarded $250 Million in Punitive Damages
10. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
11. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 PlaqueTec ... Erfassung biologischer Daten in Verbindung mit Herzerkrankungen ... Das LBS nimmt gleichzeitig mehrere Blutproben von ... und sucht erhöhte biologische Aktivitäten in erkrankten ... Entdeckung und Entwicklung neuer Medikamente und Therapeutika ...
(Date:7/28/2014)... July 28, 2014 “2014 ... Lubricant Industry” is a professional and in-depth ... market. The report introduces Lubricant basic information, ... chain structure and industry overview. This research ... domestic market as well as global industry ...
(Date:7/28/2014)... 2014 /PRNewswire/ -   JOLT , a leading technology ... join its growing portfolio of startups. Next-level tech and ... JOLT accelerator, and Cohort four is no ... Since its launch in July 2012, JOLT ... of financing. Now at 23 investments, JOLT,s portfolio has ...
(Date:7/28/2014)... --  Propeller Health , the FDA-cleared digital health solution ... Brad Towle as Senior Vice President, Business and ... company,s sales growth, customer acquisition and program expansion. ... past role in the development of accountable care organizations, ... time in the industry," said David Van Sickle ...
Breaking Biology Technology:PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 2PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 4Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 2Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 3Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 4JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2
... Study Impact on Detroit Area, DETROIT, March ... findings from its new study, Affordable Broadband:,Empowering Communities ... expanded access to education, health care and civic,involvement ... Detroit Digital Empowerment Council (DEC) that was launched,earlier ...
... LEXINGTON, Mass., March 11 Indevus,Pharmaceuticals, Inc. (Nasdaq: ... the Cowen and Company 28th Annual Health Care Conference, ... conference is being held in,Boston, Massachusetts. The presentation will ... the Investors section of the Indevus website at, http://www.indevus.com ...
... Immucor, Inc., a,global leader in providing automated ... today that it has signed a definitive,agreement ... held company,based in Warren, NJ that has ... enable rapid and comprehensive antigen,determination for donors ...
Cached Biology Technology:Study Finds Broadband Access Key to Empowerment of Minority Communities 2Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference 2Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference 3Immucor To Acquire BioArray Solutions Ltd. 2Immucor To Acquire BioArray Solutions Ltd. 3Immucor To Acquire BioArray Solutions Ltd. 4
(Date:7/28/2014)... the bug hunter, but the target of his work ... identified with special methods and instruments. Benjamin Hause, an ... Laboratory at Kansas State University, recently published an article ... is an important find in the United States. , ... know what it was," Hause said. "We used next-generation ...
(Date:7/28/2014)... -- Research and Markets has announced the ... 2014-2018" report to their offering. ... analyze biological data. These systems capture biological traits such ... and hand measurements from the subject and compare the ... purpose of a biometrics system is to identify and ...
(Date:7/28/2014)... RENO Norwegian explorer Roald Amundsen became the first ... 1911. More than 100 years later, an international team ... Research Institute (DRI) have proven that air pollution from ... 16 ice cores collected from widely spaced locations around ... created the most accurate and precise reconstruction to date ...
Breaking Biology News(10 mins):Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3Biometrics Market in Latin America 2014-2018 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3
... The 8th International Conference on Biotherapy (ICB-2010) will ... at the Universal - Los Angeles Hilton. It ... new clinical and research findings in biotherapy (living ... the 4-day conference, an internationally distinguished faculty will ...
... Scientists of the Max Delbrck Center for Molecular ... Research Center (ECRC) of MDC and Charit in ... of epithelial cells and their molecular repertoire. Dr. ... have identified a transcription factor (grainyhead-like 2, Grhl2), ...
... study that sounds a conservation alarm for the world,s vertebrate ... better, says a University of New Hampshire researcher who was ... UNH research professor of natural resources and director of the ... to "The Impact of Conservation on the Status of the ...
Cached Biology News:International Conference on Biotherapy to be held in the US 2New insights into the development of epithelial cells 2UNH's Fred Short adds seagrass data to major conservation study 2
POU domain, class 2, transcription factor 2,...
IKKbeta/IKK-2 Polyclonal Antibody 100 ug affinity purified rabbit polyclonal antibody. Reacts with human. Tested in Western blotting....
1, 2 or 8 PreMixes are included as part of the FailSafe™ PCR System....
The Hybrid Hunter Yeast Two-Hybrid System uses the activation of reporter genes to indicate positive protein-protein interactions. Two reporters are used an auxotrophic marker and lacZ....
Biology Products: